RESUMO
OBJECTIVE: To study the clinical spectrum of CACNA1A S218L mutation carriers with special attention to "early seizures and cerebral oedema after trivial head trauma (ESCEATHT)", a combination of symptoms which resembles the "juvenile head trauma syndrome". PATIENTS AND METHODS: In two patients with ESCEATHT all exons of CACNA1A were sequenced. Both patients also had hemiplegic migraine and ataxia. Subsequently, we screened the literature for S218L mutation carriers. RESULTS: In both patients, a de novo S218L mutation in the CACNA1A gene was found. In addition, we identified 11 CACNA1A S218L carriers from the literature. Of these 13 S218L mutation carriers, 12 (92%) had ataxia or cerebellar symptoms and nine (69%) had hemiplegic migraine that could be triggered by trivial head trauma. Three mutation carriers had the complete ESCEATHT phenotype. Seven (54%) had seizures (four had early post-traumatic seizures) and five (38%) had oedema as detected by MRI/CT. CONCLUSIONS: The CACNA1A S218L mutation is associated with familial hemiplegic migraine, ataxia and/or ESCEATHT. A minority of S218L mutation carriers have the complete ESCEATHT phenotype but a high percentage of patients had one or more ESCEATHT symptoms. As the S218L mutation enhances the propensity for cortical spreading depression (CSD), we postulate a role for CSD not only in hemiplegic migraine but also in early seizures and cerebral oedema after trivial head trauma. As this combination of symptoms is part of the unexplained "juvenile head trauma syndrome", a similar molecular mechanism may underlie this disorder.
Assuntos
Edema Encefálico/genética , Lesões Encefálicas/complicações , Canais de Cálcio/genética , Enxaqueca com Aura/genética , Mutação/genética , Convulsões/genética , Ataxia/etiologia , Criança , Feminino , Humanos , Masculino , Adulto JovemRESUMO
Familial hemiplegic migraine (FHM) and alternating hemiplegia of childhood (AHC) are severe neurological disorders that share clinical features. Therefore, FHM genes are candidates for AHC. We performed mutation analysis in the CACNA1A gene in a monozygotic twin pair with clinical features overlapping with both AHC and FHM and identified a novel de novo CACNA1A mutation. We provide the first evidence that a CACNA1A mutation can cause atypical AHC, indicating an overlap of molecular mechanisms causing AHC and FHM. These results also suggest that CACNA1A mutation scanning is indicated in patients with a severe neurological phenotype that includes paroxysmal (alternating) hemiplegia.
Assuntos
Canais de Cálcio/genética , Hemiplegia/genética , Transtornos de Enxaqueca/genética , Gêmeos Monozigóticos/genética , Adolescente , Ligação Genética , Predisposição Genética para Doença/genética , Humanos , Masculino , MutaçãoRESUMO
Due to frame-shifting mutations in the DMD gene that cause dystrophin deficiency, Duchenne muscular dystrophy (DMD) patients suffer from lethal muscle degeneration. In contrast, mutations in the allelic Becker muscular dystrophy (BMD) do not disrupt the translational reading frame, resulting in a less severe phenotype. In this study, we explored a genetic therapy aimed at restoring the reading frame in muscle cells from DMD patients through targeted modulation of dystrophin pre-mRNA splicing. Considering that exon 45 is the single most frequently deleted exon in DMD, whereas exon (45+46) deletions cause only a mild form of BMD, we set up an antisense-based system to induce exon 46 skipping from the transcript in cultured myotubes of both mouse and human origin. In myotube cultures from two unrelated DMD patients carrying an exon 45 deletion, the induced skipping of exon 46 in only approximately 15% of the mRNA led to normal amounts of properly localized dystrophin in at least 75% of myotubes. Our results provide first evidence of highly effective restoration of dystrophin expression from the endogenous gene in DMD patient-derived muscle cells. This strategy may be applicable to not only >65% of DMD mutations, but also many other genetic diseases.
Assuntos
Distrofina/biossíntese , Distrofina/genética , Éxons , Deleção de Genes , Músculos/citologia , Distrofia Muscular de Duchenne/genética , Oligonucleotídeos Antissenso , Alelos , Animais , Sequência de Bases , Linhagem Celular , Humanos , Imuno-Histoquímica , Camundongos , Microscopia de Fluorescência , Modelos Genéticos , Dados de Sequência Molecular , Músculos/patologia , Oligonucleotídeos Antissenso/farmacologia , Fenótipo , Biossíntese de Proteínas , RNA/metabolismo , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Análise de Sequência de DNA , Fatores de Tempo , TransfecçãoRESUMO
Within one X-linked muscular dystrophy family, different phenotypes for three males occurred: (1) a severely affected Becker patient with cardiomyopathy, (2) a mildly affected Becker patient, and (3) an apparently healthy male with elevated serum CK levels. In the muscle biopsy specimen of patient2 one out of four antibodies (NCL-DYS1) showed absence of dystrophin. The protein truncation test detected a truncated dystrophin for both muscle tissue and lymphocytes of this patient next to an additional near normal size fragment in muscle. Genomic sequence analysis revealed a nonsense mutation in exon 29 (4148C > T) of the dystrophin gene. Sequence analysis of the mRNA fragment of the larger peptide showed skipping of exon 29, restoring an open reading frame. Consequently, the epitope of the antibody NCL-DYS1 is mapped to exon 29. The variable clinical features of the three relatives from healthy to severely affected therefore seems to be related to the level of skipping of exon 29. This finding underscores the future potential of gene therapeutic strategies aimed at inducing exon skipping in Duchenne muscular dystrophy, to generate a much milder disease.
Assuntos
Códon sem Sentido/genética , Distrofina/genética , Éxons/genética , Distrofias Musculares/genética , Fenótipo , Adulto , Biópsia , Análise Mutacional de DNA , Distrofina/metabolismo , Elementos Facilitadores Genéticos , Feminino , Variação Genética/fisiologia , Humanos , Técnicas Imunoenzimáticas , Linfócitos/fisiologia , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/citologia , Músculo Esquelético/fisiologia , Linhagem , Splicing de RNARESUMO
Detection of large rearrangements in the dystrophin gene in Duchenne and Becker muscular dystrophy is possible in about 65-70% of patients by Southern blotting or multiplex PCR. Subsequently, carrier detection is possible by assessing the intensity of relevant bands, but preferably by a non-quantitative test method. Detection of microlesions in Duchenne and Becker muscular dystrophy is currently under way. Single strand conformational analysis, heteroduplex analysis, and the protein truncation test are mostly used for this purpose. In this paper we review the available methods for detection of large and small mutations in patients and in carriers and propose a systematic approach for genetic analysis and genetic counselling of DMD and BMD families, including prenatal and preimplantation diagnosis.
Assuntos
Distrofina/genética , Distrofias Musculares/genética , Análise Mutacional de DNA , Distrofina/análise , Feminino , Aconselhamento Genético , Técnicas Genéticas , Heterozigoto , Humanos , Masculino , Mosaicismo , Músculo Esquelético/química , Distrofias Musculares/diagnóstico , Distrofias Musculares/fisiopatologia , Ácidos Nucleicos Heteroduplexes/análise , Linhagem , Polimorfismo Conformacional de Fita Simples , Gravidez , Diagnóstico Pré-Implantação , Diagnóstico Pré-Natal , Proteínas/análise , Fatores de RiscoRESUMO
We have used an RNA based mutation detection method to screen the total coding region of the dystrophin gene of a Duchenne and a Becker muscular dystrophy patient in whom DNA based mutation detection methods have so far failed to detect mutations. By RT-PCR and the protein truncation test (PTT) we could identify point mutations in both cases. DMD patient DL184.3 has a T-->A mutation in intron 59 at position -9, creating a novel splice acceptor site for exon 60. As a result seven intronic bases are spliced into the mRNA, causing a frameshift and premature translation termination 20 codons downstream. Since this patient had died and only fibroblasts were available, we applied MyoD induced myodifferentiation of stored fibroblasts to enhance muscle specific gene expression. With the results of this mutation analysis, prenatal diagnosis could subsequently be performed in this family. BMD patient BL207.1 carries a G-->C mutation at position +5 of intron 64, disrupting the splice donor consensus sequence and activating a cryptic splice donor site 57bp downstream. The inclusion of these 57 intronic bases in the mRNA leaves the reading frame open and results in the insertion of 19 amino acids into the cysteine rich domain of dystrophin. Interestingly, this insertion in a part of the dystrophin considered to interact with the dystrophin binding complex of the sarcolemma is apparently compatible with mild BMD-like clinical features. Both mutations reported are missed by analysis of multiplex PCR products designed for deletion screening of the coding region. Extrapolation from existing point mutation detection efficiencies by DNA and RNA based methods emphasises that RNA based methods are more sensitive and that most of the remaining undetected mutations may affect splice or branch sites or create cryptic splice sites.
Assuntos
Distrofina/genética , Distrofias Musculares/genética , Mutação , Reação em Cadeia da Polimerase/métodos , Adolescente , Sequência de Aminoácidos , Sequência de Bases , Western Blotting , Diferenciação Celular/genética , Criança , Cisteína/química , Cisteína/genética , Elementos de DNA Transponíveis , Distrofina/química , Feminino , Fibroblastos/citologia , Heterozigoto , Humanos , Masculino , Dados de Sequência Molecular , Distrofias Musculares/diagnóstico , Proteína MyoD/genética , Linhagem , Gravidez , Diagnóstico Pré-Natal , Splicing de RNA , TransfecçãoRESUMO
Duchenne muscular dystrophy (DMD) is frequently associated with myocardial involvement. Dystrophin, the DMD protein, is found at the plasmamembrane of striated muscle fibers. Although dystrophin is missing in most or all muscle fibers of DMD patients, cardiac muscle is not as severely affected as skeletal muscle. Therefore it is of great importance to study the expression of dystrophin in normal cardiac muscle. We performed immunohistochemical studies and examined cardiac muscle of fetuses of 8 to 13 weeks of development on dystrophin expression. At these stages dystrophin is observed in the myocytes of the developing ventricular conduction system and in the atrial cardiomyocytes. Dystrophin was absent from the heart of a 12-week-old DMD fetus.
Assuntos
Distrofina/biossíntese , Sistema de Condução Cardíaco/embriologia , Sistema de Condução Cardíaco/metabolismo , Coração/embriologia , Miocárdio/metabolismo , Anticorpos Monoclonais/imunologia , Creatina Quinase/metabolismo , Distrofina/imunologia , Feto/metabolismo , Idade Gestacional , Sistema de Condução Cardíaco/ultraestrutura , Humanos , Técnicas Imunoenzimáticas , Microscopia Imunoeletrônica , Miocárdio/citologia , Miocárdio/ultraestruturaRESUMO
This multidisciplinary study was undertaken to record the variation in gene and protein expression in a large cohort of patients with well defined clinical phenotypes. The patients, whose ages ranged from 4 years to 66 years, spanned a wide range of disease severity. They represented the first 100 patients who had been examined in Newcastle, had undergone a muscle biopsy, and provided a blood sample for DNA analysis. The study had three aims: to observe any trends in the analyses across the clinical groups, to correlate gene and protein expression in individual patients, and to use the data collected to assess the relative usefulness of different techniques in the diagnosis and prognosis of patients with Duchenne and Becker dystrophy (DMD/BMD). In part 1, we describe the clinical assessment of the patients and the trends that were observed across the cohort. The patients were divided into seven groups. Group 1 had severe DMD (n = 21), group 2 had milder DMD (n = 20), group 3 were intermediate D/BMD patients (n = 9), group 4 had severe BMD (n = 5), and group 5 were more typical BMD patients (n = 31). Some patients were too young to be classified (n = 7) and a group of all the female patients were also classified separately (n = 7). The number of DMD and BMD patients was about equal, in accord with disease prevalence in the north of England, but an unusually high proportion were sporadic cases. Dystrophin labelling (performed with up to three antibodies) on both blots and sections increased gradually across the clinical groups. All histopathological indices, except the proportion of fat in biopsy sections, showed clear trends across the groups.
Assuntos
Distrofina/biossíntese , Distrofias Musculares/genética , Adolescente , Adulto , Análise de Variância , Anticorpos Monoclonais , Western Blotting , Distribuição de Qui-Quadrado , Criança , Pré-Escolar , Estudos de Coortes , Creatina Quinase/sangue , Distrofina/química , Distrofina/genética , Feminino , Deleção de Genes , Ligação Genética , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Família Multigênica , Músculos/metabolismo , Distrofias Musculares/metabolismo , Distrofias Musculares/patologia , Pacientes/classificação , Índice de Gravidade de Doença , Cromossomo XRESUMO
This report is the second part of a trilogy from a multidisciplinary study which was undertaken to record the relationships between clinical severity and dystrophin gene and protein expression. The aim in part 2 was to correlate the effect of gene deletions on protein expression in individual patients with well defined clinical phenotypes. Among the DMD patients, most of the deletions/duplications disrupted the open reading frame, but three patients had in frame deletions. Some of the intermediate D/BMD patients had mutations which were frameshifting while others were in frame. All of the deletions/duplications in the BMD patients maintained the open reading frame and 25/26 deletions in typical BMD group 5 started with exon 45. The deletion of single exon 44 was the most common mutation in patients from groups 1 to 3. Dystrophin was detected in sections and blots from 58% of the DMD patients with a size that was compatible with synthesis from mRNA in which the reading frame had been restored. Certain deletions were particularly associated with the occurrence of limited dystrophin synthesis in DMD patients. For example, 9/11 DMD patients missing single exons had some detectable dystrophin labelling compared with 10/24 who had deletions affecting more than one exon. All patients missing single exon 44 or 45 had some dystrophin. Deletions starting or finishing with exons 3 or 51 (8/9) cases were usually associated with dystrophin synthesis whereas those starting or finishing with exons 46 or 52 (11/11) were not. Formal IQ assessments (verbal, performance, and full scores) were available for 47 patients. Mean IQ score among the DMD patients was 83 and no clear relationship was found between gene mutations and IQ. The mutations in patients with a particularly severe deficit of verbal IQ were spread throughout the gene.
Assuntos
Distrofina/biossíntese , Distrofias Musculares/genética , Adolescente , Adulto , Idoso , Western Blotting , Criança , Pré-Escolar , Estudos de Coortes , Distrofina/química , Distrofina/genética , Feminino , Mutação da Fase de Leitura , Deleção de Genes , Ligação Genética , Genótipo , Humanos , Deficiência Intelectual/genética , Testes de Inteligência , Masculino , Pessoa de Meia-Idade , Família Multigênica , Distrofias Musculares/metabolismo , Distrofias Musculares/patologia , Fenótipo , Índice de Gravidade de Doença , Cromossomo XRESUMO
This report is the third part of a trilogy from a multidisciplinary study which was undertaken to investigate gene and protein expression in a large cohort of patients with well defined and diverse clinical phenotypes. The aim of part 3 was to review which of the analytical techniques that we had used would be the most useful for differential diagnosis, and which would provide the most accurate indication of disease severity. Careful clinical appraisal is very important and every DMD patient was correctly diagnosed on this basis. In contrast, half of the sporadic BMD patients and all of the sporadic female patients had received different tentative diagnoses based on clinical assessments alone. Sequential observations of quantitative parameters (such as the time taken to run a fixed distance) were found to be useful clinical indicators for prognosis. Intellectual problems might modify the impression of physical ability in patients presenting at a young age. Histopathological assessment was accurate for DMD but differentiation between BMD and other disorders was more difficult, as was the identification of manifesting carriers. Our data on a small number of women with symptoms of muscle disease indicate that abnormal patterns of dystrophin labelling on sections may be an effective way of differentiating between female patients with a form of limb girdle dystrophy and those carrying a defective Xp21 gene. Dystrophin gene analysis detects deletions/duplications in 50 to 90% of male patients and is the most effective non-invasive technique for diagnosis. Quantitative Western blotting, however, would differentiate between all Xp21 and non-Xp21 male patients. In this study we found a clear relationship between increased dystrophin abundance (determined by densitometric analysis of blots) and clinical condition, with a correlation between dystrophin abundance and the age at loss of independent mobility among boys with DMD and intermediate D/BMD. This indicates that blotting is the most sensitive and accurate technique for diagnosis and prognosis.
Assuntos
Distrofina/genética , Distrofias Musculares/diagnóstico , Distrofias Musculares/genética , Adolescente , Adulto , Idoso , Western Blotting , Criança , Pré-Escolar , Estudos de Coortes , Creatina Quinase/sangue , Diagnóstico Diferencial , Distrofina/biossíntese , Feminino , Mutação da Fase de Leitura , Deleção de Genes , Ligação Genética , Genótipo , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Distrofias Musculares/metabolismo , Distrofias Musculares/patologia , Fenótipo , Prognóstico , Índice de Gravidade de Doença , Cromossomo XRESUMO
Details of disease progression and dystrophin expression are presented for three patients with Duchenne muscular dystrophy (DMD) who unexpectedly had intragenic deletions which maintained the open reading frame for mRNA translation. Analysis of dystrophin in muscle biopsies showed variable dystrophin synthesis in all three patients. Two with relatively small deletions (missing exons 10-13 and 52-55) had low levels of dystrophin which were comparable to those found in many DMD patients. The third patient (with a larger deletion which removed exons 3-25) produced dystrophin in the high abundance which is normally associated with patients who have Becker muscular dystrophy. This is the first time that a patient has been described with the clinical phenotype of DMD, a large amount of dystrophin which was correctly localized at the periphery of muscle fibres and an in-frame deletion of exons in the amino terminal domain.
Assuntos
Distrofina/genética , Deleção de Genes , Distrofias Musculares/genética , Fases de Leitura Aberta , Biópsia , Western Blotting , Criança , Pré-Escolar , Cromossomos Humanos Par 21 , Distrofina/biossíntese , Éxons , Expressão Gênica , Humanos , Masculino , Músculos/química , Distrofias Musculares/diagnósticoRESUMO
Among 85 patients with Duchenne and Becker muscular dystrophy, 29 were found to have mutations which disrupted the open reading frame for dystrophin. Thus any dystrophin detected in this group of patients should consist of the severely truncated polypeptides that represent prematurely terminated translation products. Dystrophin was detected in blots from 17/29 biopsies and the observed sizes of the polypeptides were compared with predicted sizes calculated in two ways: if translation was terminated at the stop codon generated by each frameshifting deletion, and if the reading frame was restored and translation proceeded. In every case the observed size matched the size predicted on the basis of a restored reading frame. This was in accord with immunocytochemical labelling of scattered dystrophin positive fibres which were found on serial sections labelled with antibodies to both the rod and C-terminal domains. Thus analysis at the protein level supports genetic evidence of exon skipping as a mechanism which restores frameshifting mutations in some fibres.
Assuntos
Distrofina/genética , Deleção de Genes , Distrofias Musculares/genética , Fases de Leitura Aberta , Adolescente , Anticorpos Monoclonais , Criança , Desoxirribonuclease HindIII , Distrofina/biossíntese , Distrofina/química , Mutação da Fase de Leitura , Humanos , Masculino , Terminação Traducional da Cadeia Peptídica , Biossíntese de ProteínasRESUMO
A group of 44 monoclonal antibodies (mAbs) raised against the central helical rod (25 mAbs) and C-terminal (19 mAbs) regions of dystrophin were prepared using trpE recombinant fusion proteins as immunogens. Some mAbs cross-react with the structurally related proteins, alpha-actinin and utrophin. Epitope mapping revealed uneven distribution of mAb-binding sites, no mAbs being produced against the C-terminal end of the helical fragment or the cysteine-rich region of the C-terminal dystrophin fragment. The failure of these large regions of the recombinant immunogens to elicit anti-dystrophin antibodies may be because of their inability to fold into the correct dystrophin-like conformation. The mAbs were selected for their ability to recognize 427 kDa dystrophin on Western blots after SDS/PAGE, and/or for immunostaining of the membrane in frozen muscle sections. Although some mAbs obtained by Western-blot screening failed to bind native dystrophin in frozen muscle sections, successful binding could be obtained after SDS or urea treatment of the tissue section to expose the epitopes. This increases the range of mAbs available for detection of dystrophin deletions in muscular dystrophy and evaluation of myoblast therapy.
Assuntos
Anticorpos Monoclonais/imunologia , Distrofina/imunologia , Sequência de Aminoácidos , Animais , Distrofina/genética , Epitopos , Humanos , Camundongos , Dados de Sequência Molecular , Proteínas Recombinantes de Fusão/imunologia , Mapeamento por RestriçãoRESUMO
We have performed immunohistochemical studies on muscle tissue of three 12 week old fetuses at risk for DMD, using antisera directed against regions located NH2-proximally and centrally in the rod shaped spectrin-like domain and against the COOH-terminus of dystrophin. All three fetuses had a family history of DMD. Truncated dystrophins were identified in all three cases by a positive reaction with the NH2-proximal antibody, different reactions with the central antibody, and a negative reaction with the COOH-terminal antibody. These data indicate that a panel of antibodies would, in principle, permit 'immunological' mapping of dystrophin mutations. This is diagnostically important in the 35% of families where no mutation is detectable at the DNA level. Secondly, by using this mapping technique it may also become possible to identify the at risk haplotype when DNA analysis is not informative. This may be of great value in DMD carrier detection.
Assuntos
Distrofina/análise , Doenças Fetais/genética , Músculos/embriologia , Distrofias Musculares/genética , Distrofina/genética , Feminino , Doenças Fetais/embriologia , Doenças Fetais/metabolismo , Haplótipos , Heterozigoto , Humanos , Imuno-Histoquímica , Masculino , Músculos/química , Distrofias Musculares/embriologia , Distrofias Musculares/metabolismo , Mutação/genética , Linhagem , RiscoRESUMO
Duchenne and Becker muscular dystrophy are caused by defects in dystrophin synthesis. Using affinity-purified polyclonal anti-dystrophin antibodies, we have studied immunohistochemically the subcellular localization of dystrophin in embryonic, fetal, and adult human skeletal muscle. In the embryonic stages dystrophin first appears in the sarcoplasm at the peripheral ends of the myotubes, immediately adjacent to the tendons, whereas in fetal stages dystrophin is found throughout the entire myofibers. In agreement with literature data, in adult muscle dystrophin expression was found to be restricted to the sarcolemma. The sarcoplasmic localization in embryonic and fetal tissue and the sarcolemmal localization of dystrophin in mature muscle suggests the accumulation of dystrophin in the cytoplasm prior to its integration into the membrane. These results increase our knowledge of the ontogenesis of dystrophin and may lead to a better understanding of the great diversity in pathological cases of Duchenne and Becker muscular dystrophy.
Assuntos
Distrofina/análise , Músculos/química , Animais , Western Blotting , Distrofina/genética , Feto/química , Expressão Gênica/fisiologia , Humanos , Técnicas Imunoenzimáticas , Camundongos , Camundongos Endogâmicos , Sarcolema/química , Retículo Sarcoplasmático/químicaRESUMO
Muscle dystrophin mRNAs from Duchenne (DMD) and Becker (BMD) patients with internal deletion of the DMD gene were quantitated and sequenced. In all cases (eight DMD and three BMD), truncated mature transcripts were found, and their amount was correlated to the clinical phenotype and to the reading frame. We focused on four cases that were apparently not in agreement with the reading frame rule. In two DMD cases, slightly reduced amounts of in-frame truncated mRNA are present but no dystrophin is detected, suggesting impaired translation and/or instability of the protein. In two BMD patients with out-of-frame deletions, the presence of minor in-frame alternatively spliced mRNA species is congruent with the observed truncated dystrophin and the mild phenotype.
Assuntos
Deleção Cromossômica , Distrofina/genética , Amplificação de Genes , Genes , Distrofias Musculares/genética , RNA Mensageiro/genética , Transcrição Gênica , Sequência de Bases , Éxons , Humanos , Dados de Sequência Molecular , Distrofias Musculares/classificação , Sondas de Oligonucleotídeos , Splicing de RNA , Fases de Leitura , Mapeamento por RestriçãoRESUMO
A monoclonal antibody, MANDYS141, binds to both dystrophin and actinin on Western blots (SDS-denatured), but only to actinin in frozen sections of human muscle (native conformation). It differs from a polyclonal cross-reacting antiserum in that it binds to several muscle isoforms of actinin (smooth, fast and slow) from man, mouse and chicken and recognises a quite different part of the proposed triple-helical region of dystrophin (amino acids 1750-2248). The results suggest that structural homologies between actinin and dystrophin occur more than once in their central helical regions and provide experimental support for an actinin-like central rod model for dystrophin.
Assuntos
Actinina/análise , Anticorpos Monoclonais , Distrofina/análise , Actinina/química , Animais , Anticorpos Monoclonais/imunologia , Especificidade de Anticorpos , Western Blotting , Galinhas , Distrofina/química , Epitopos/imunologia , Humanos , Camundongos , Microscopia de Fluorescência , Peso Molecular , Músculos/química , Distrofia Muscular Animal/metabolismoRESUMO
An immunohistochemical study was carried out on a twelve-week old fetus, aborted for high risk of Duchenne muscular dystrophy. Southern and FIGE analysis showed an intragenic duplication in the DMD gene, which had previously resulted in a severe Duchenne phenotype in three relatives. Polyclonal antibodies directed against the NH2-terminal half of dystrophin showed a positive reaction an a similar distribution of dystrophin in the skeletal myotubes of a twelve-week old normal fetus and the affected fetus. In contrast, a polyclonal antibody directed against the COOH-terminus of dystrophin, i.e., distal to the mutation in this family, did only react with the myotubes of the normal fetus and not with those of the affected fetus. This indicates the presence of a truncated dystrophin in the affected fetus. Apparently at this stage, before binding of dystrophin to the sarcolemma, no distinction is made yet between normal and abnormal dystrophins. This implies that the potential to bind to the sarcolemma could be a major point of discrimination between normal and defective dystrophins. The truncated dystrophin will probably be degraded in a later stage during fetal development. So it appears that the use of dystrophin immunostaining to confirm high Duchenne risk abortions requires great caution. To prevent false-positive results, the combined use of NH2- and COOH-terminal antibodies is mandatory.